Compassionate Access Programme
Patients with localised pancreatic cancer have variable access to precision radiotherapy in the United Kingdom. The n-SARS-CoV-2 pandemic has further disadvantaged this patient group by reducing the availability and safety of surgery and chemotherapy. The GenesisCare Foundation Compassionate Access Programme will make available MRI-guided stereotactic ablative radiotherapy (SABR) on the ViewRay MRIdian platform, without cost, to NHS patients with localised pancreatic cancer. The programme will generate preliminary clinical and patient-reported outcome data on a UK patient cohort that will act as a pilot phase prior to dose escalation within an ethically-approved basket study; inform the design of subsequent randomised clinical trials; and help to embed SABR in UK oncology practice.
This GenesisCare Foundation Compassionate Access Programme is made possible by funding from The GenesisCare Foundation, Pancreatic Cancer Research Fund and ViewRay. Research is undertaken through a partnership with the University of Oxford.